Refine
Has Fulltext
- yes (88)
Is part of the Bibliography
- yes (88)
Year of publication
Document Type
- Journal article (87)
- Doctoral Thesis (1)
Keywords
- cancer (5)
- colorectal cancer (5)
- multiple myeloma (4)
- NRF2 (3)
- apoptosis (3)
- metastasis (3)
- therapy (3)
- tumor microenvironment (3)
- ATF4 (2)
- CRC (2)
- Germany (2)
- HNSCC (2)
- NFATc1 (2)
- NSCLC (2)
- SUV (2)
- angiogenesis (2)
- autophagy (2)
- carcinomas (2)
- chromatin (2)
- eHealth (2)
- fatigue (2)
- head and neck cancer (2)
- immune response (2)
- machine learning (2)
- melanoma (2)
- metabolomics (2)
- mind–body intervention (2)
- outcome (2)
- p53 (2)
- pediatric adrenocortical cancer (2)
- pediatric adrenocortical tumor (2)
- psycho-oncology (2)
- psychoeducation (2)
- radiotherapy (2)
- treatment (2)
- 3D lung tumor tissue models (1)
- ALT (1)
- AMPK (1)
- AOM/DSS (1)
- ATG7 (1)
- ATM (1)
- ATRX (1)
- Akt (1)
- Alzheimer’s dementia (1)
- B cell receptor (BCR) (1)
- B-cell lymphoma (1)
- BM (1)
- Bruton's tyrosine kinase inhibitor CC-292 (1)
- Burkitt lymphoma (1)
- Burkitt lymphoma (BL) (1)
- CA19-9 (1)
- CD30 (1)
- CD44 (1)
- CHAC1 (1)
- CMR (1)
- COVID-19 (1)
- COVID-19 pandemic (1)
- CX5461 (1)
- CYP24A1 (1)
- CYP2W1 (1)
- Carfilzomib (1)
- Chains (1)
- Clonality (1)
- Compound 3k (1)
- Cushing (1)
- Cushing syndrome (1)
- Cushing’s syndrome (1)
- DASA-58 (1)
- DCM genetic background (1)
- DNA repair protraction (1)
- DNA-PK (1)
- DUB inhibitor (1)
- Delta Repertoire (1)
- Design (1)
- EGF (1)
- EGFR (1)
- EMT (1)
- EZH2 (1)
- Epitope (1)
- FBXW7 (1)
- FGF-pathway (1)
- FGFR (1)
- FGFR-inhibitors (1)
- FasL (1)
- Foxp3 (1)
- Frequency (1)
- GPCRs (1)
- GSH (1)
- Galectin-1 (1)
- H2A histone family member X (H2AX) (1)
- HNSC (1)
- HSC (1)
- Hans algorithm (1)
- IR (1)
- Improved survival (1)
- Intestinal Intraepithelial Lymphocy (1)
- JAK inhibitor (1)
- KEAP1 (1)
- KRAS biomarker signatures (1)
- LAMN (1)
- Lymph2Cx assay (1)
- Lymphoma (1)
- MAPK signaling cascades (1)
- MAX (1)
- MITF-low (1)
- MIZ1 (1)
- MTB (1)
- MTL30 (1)
- MYC (1)
- MYCN (1)
- Myelom (1)
- NFE2L2 (1)
- NFκB (1)
- NOP10 (1)
- NVP-BEZ235 (1)
- Nfatc1 (1)
- Novel PI3K (1)
- PCa (1)
- PET (1)
- PET/CT (1)
- PI3K (1)
- PKM2 (1)
- PPGL (1)
- PSMA (1)
- PSMA-TV (1)
- PTEN (1)
- Plasmozytom (1)
- Proteasominhibitor (1)
- RBM20 mutations (1)
- RCC (1)
- RNA splicing (1)
- RNAPOL1 (1)
- Rectal cancer (1)
- Rituximab (1)
- SARS-CoV-2 (1)
- SCC (1)
- SLC7A11 (1)
- SSI (1)
- Solid tumors (1)
- Sprue (1)
- T-cells (1)
- TERT (1)
- TGF-alpha (1)
- TKI (1)
- TME (1)
- TNFα (1)
- TPCA1 (1)
- TXNIP (1)
- Tp63 (1)
- Tregs (regulatory T cells) (1)
- UMAP (1)
- USP25 (1)
- USP28 (1)
- Usage (1)
- VDR (1)
- Warburg effect (1)
- Wilms tumor (1)
- YAP5SA (1)
- Yoga (1)
- ZfKD (1)
- activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL) (1)
- activating transcription factor 4 (ATF4) (1)
- acute appendicitis (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- adjuvant treatment (1)
- adrenal cancer (1)
- adrenal glands (1)
- adrenal surgery (1)
- adrenal tumours (1)
- adrenalectomia (1)
- adrenocortical adenocarcinoma (1)
- adrenocortical cancer (1)
- adrenocortical carcinoma (1)
- adrenocortical carcinoma (ACC) (1)
- adrenocortical development (1)
- adrenocortical tumors (1)
- age (1)
- anastomosis (1)
- ancistrocladinium A (1)
- angiogenesis inhibitors (1)
- anti-inflammatory cytokines (1)
- antibiotics (1)
- antiphospholipid syndrome (1)
- anxiety (1)
- aplastic anemia (1)
- appendectomy (1)
- appendicitis (1)
- appendix (1)
- ataxia teleagiectasia mutated (ATM) (1)
- autoantibodies (1)
- bacterial infections (1)
- biased signaling (1)
- biomarker (1)
- biomarkers (1)
- blood pressure (1)
- bone adaptation (1)
- bone marrow failure (1)
- bone marrow immune-microenvironment (1)
- bone metastasis (1)
- boolean in silico models (1)
- brain metastases (1)
- c-MYC (1)
- caco-2 cells (1)
- cancer care (1)
- cancer diagnosis (1)
- cancer metabolism (1)
- cancer predisposition syndromes (1)
- cancer treatment (1)
- cancer-induced bone disease (1)
- cancer-testis antigens (1)
- cardiac thrombi (1)
- cell biology (1)
- cell cycle (1)
- cell migration (1)
- cell of origin (1)
- cellular stress response (1)
- cerebral metastases (1)
- cholestasis (1)
- chronic IBD model (1)
- clinical malformations (1)
- clinical trials (1)
- cognitive impairment (1)
- colon (1)
- colon resection (1)
- complementary alternative medicine (1)
- complementary medicine (1)
- complication (1)
- confounders (1)
- conventional laparoscopic appendectomy (1)
- cost-effectiveness (1)
- cutaneous T-cell-lymphoma (1)
- cyclosporin A (1)
- cytopenia (1)
- depression (1)
- developmental biology (1)
- diffuse large B-cell lymphoma (1)
- disorder of immunity (1)
- distress (1)
- donor-site morbidity (1)
- drug repurposing (1)
- drug resistance (1)
- drug therapy (1)
- eEF1A1 (1)
- ectodomain cleavage (1)
- effector Treg (eTreg) (1)
- efficacy (1)
- engaging aantibody (1)
- epidemiology (1)
- evolutionary genetics (1)
- fibroblast activation protein (1)
- fibrosis (1)
- follow-up (1)
- free skin grafts (1)
- free survival (1)
- gammadelta T cells (1)
- gastrointestinal infection (1)
- gene expression (1)
- general medicine (1)
- genetic markers (1)
- genome (1)
- geriatric (1)
- glycolysis (1)
- heart (1)
- heart failure (1)
- helminthes (1)
- hematopoiesis (1)
- hematopoietic stem cells (1)
- homeostasis (1)
- hormones (1)
- hypercortisolism (1)
- hypertension (1)
- hypogammaglobulinemia (1)
- hypoxia (1)
- immune infiltration (1)
- immune-checkpoint inhibitor (1)
- immunohistochemistry techniques (1)
- immunosurveillance (1)
- immunotherapy (1)
- individual mind state (1)
- induction (1)
- inflammation (1)
- inhibitor (1)
- integrated stress response (1)
- interactome (1)
- invasion (1)
- isturisa (1)
- kidney cancer (1)
- laparoscopic appendectomy (1)
- large cell transformation (1)
- left hemicolectomy (1)
- lifestyle habits (1)
- lineage (1)
- lineage differentiation (1)
- liquid chromatography–tandem mass spectrometry (LC–MS/MS) (1)
- long-term effects (1)
- low-grade mucinous neoplasm (1)
- lymphocytes (1)
- lymphoma (1)
- mRNA (1)
- mTOR Inhibitor (1)
- mass spectrometry (1)
- matrix metalloproteinase (1)
- mechanical loading (1)
- medical therapy (1)
- meta-analysis (1)
- methylation (1)
- metyrapone (1)
- miR (1)
- miRNA (1)
- mind-body-intervention (1)
- mitotane (1)
- molecular alterations (1)
- molecular imaging (1)
- molecular subtypes (1)
- monogenetic cardiomyopathies (1)
- morphological features (1)
- mortality (1)
- motivational level (1)
- multicenter (1)
- mutation screening (1)
- mutation triggers (1)
- mycosis fungoides (1)
- myocardial infarction (1)
- naphthylisoquinoline alkaloids (1)
- negative pressure wound therapy (1)
- nephroblastoma (1)
- nephroblastomatosis (1)
- network pharmacology (1)
- neuroblastoma (1)
- neuroblastoma – diagnosis (1)
- neurofilament light chain (1)
- nuclear localization (1)
- octogenarians (1)
- octogenerians (1)
- older adult (1)
- oncogenic YAP (1)
- oncology (1)
- open appendectomy (1)
- open wound treatment (1)
- operative (1)
- oral potentially malignant disorders (1)
- osilodrostat (1)
- outcomes research (1)
- outreach (1)
- pancreatic adenocarcinoma (PDAC) (1)
- pancreatic cancer (1)
- panel sequencing (1)
- paraganglioma (1)
- parathyroid hormone 1 receptor (1)
- patient access (1)
- pediatric (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical carcinoma (1)
- pheochromocytoma (1)
- pheochromocytoma/paraganglioma (1)
- phosphorylated tau protein (1)
- phosphorylation (1)
- plasma NMR (1)
- platelet-rich fibrin (1)
- postoperative inflammation (1)
- preanalytical conditions (1)
- precision medicine (1)
- precision oncology (1)
- predictive factors (1)
- primary aldosteronism (1)
- primary cutaneous follicular B-cell lymphoma (1)
- pro-inflammatory cytokines (1)
- prognostic biomarker (1)
- prognostic factors (1)
- prognostic-biomarkers (1)
- prospective studies (1)
- prostate adenocarcinoma (1)
- prostate cancer (1)
- proteasome inhibitor resistance (1)
- proteasome subunit beta type-5 (PSMB5) (1)
- protein expression (1)
- protein synthesis (1)
- protozoa infections (1)
- radial forearm flap (1)
- radiation response (1)
- radioligand therapy (1)
- radiosensibility (1)
- radiotherapy (RT) (1)
- real world data (1)
- recurrence (1)
- recurrence free survival (1)
- reminder e-mails (1)
- renal cell carcinoma (1)
- renal function (1)
- ribosome (1)
- risk factors and etiology (1)
- risk stratification (1)
- robotic surgery (1)
- secondary skin closure (1)
- single-port appendectomy (1)
- skeletal mechanobiology (1)
- small interferring RNA (1)
- squamous (1)
- stem-cell transplantation (1)
- stemness (1)
- steroid measurement (1)
- stress (1)
- supportive care intervention (1)
- surgery (1)
- surgical (1)
- surgical oncology (1)
- surgical procedures (1)
- surgical site infection (1)
- surgical site infections (1)
- symptom burden (1)
- systematic review (1)
- t-SNE (1)
- targeted combination therapy (1)
- targeted sequencing (1)
- taxane (1)
- telomeres (1)
- thiol starvation (1)
- timing (1)
- tofacitinib (1)
- transcription (1)
- transcriptome (1)
- transcriptomic analysis (1)
- transcriptomics (1)
- translation initiation (1)
- treatment regimens (1)
- tumor surveillance (1)
- tyrosine kinase inhibitors (1)
- venous infiltration (1)
- visual clustering (1)
- vitamin D (1)
- vitamin D receptor (1)
- volume (1)
- wound infection (1)
- ΔNp63 (1)
Institute
- Comprehensive Cancer Center Mainfranken (88) (remove)
Sonstige beteiligte Institutionen
- Zentraleinheit Klinische Massenspektrometrie (3)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (1)
- Interdisciplinary Center for Clinical Research (1)
- Lehrstuhl für Regeneration Muskuloskelettaler Gewebe (1)
- Mildred Scheel Early Career Center (1)
- Muskuloskelettales Centrum Würzburg (MCW) (1)
EU-Project number / Contract (GA) number
- 633983 (2)
- 232944 (1)
- BWF/H/52228/2012/13.10.10-1/3.4,6 (1)
RBM20 mutations account for 3 % of genetic cardiomypathies and manifest with high penetrance and arrhythmogenic effects. Numerous mutations in the conserved RS domain have been described as causing dilated cardiomyopathy (DCM), whereas a particular mutation (p.R634L) drives development of a different cardiac phenotype: left-ventricular non-compaction cardiomyopathy. We generated a mutation-induced pluripotent stem cell (iPSC) line in which the RBM20-LVNC mutation p.R634L was introduced into a DCM patient line with rescued RBM20-p.R634W mutation. These DCM-634L-iPSC can be differentiated into functional cardiomyocytes to test whether this RBM20 mutation induces development of the LVNC phenotype within the genetic context of a DCM patient.